Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression
Alzheimer's & Dementia · 2023-03 · 19 (3) · 821-830
DOI: 10.1002/alz.12708 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 16.06.2022. Verfasst von Abigail Dove und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Dementia, Cognitive Dysfunction, Multimorbidity, Disease Progression. Die Arbeit wurde bisher 120-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Swedish Ministry of Health and Social Affairs, the Swedish Research Council, the Swedish Council for Health Working Life and Welfare.
Themen: Demenz
Abstract (Originalsprache)
Introduction
Cardiometabolic diseases (CMDs) have been individually associated with adverse cognitive outcomes, but their combined effect has not been investigated.
Methods
A total of 2577 dementia‐free participants 60 years of age or older were followed for 12 years to observe changes in cognitive function and to detect incident cognitive impairment, no dementia (CIND) and dementia. CMDs (including type 2 diabetes, heart disease, and stroke) were assessed at baseline through medical records and clinical examinations. Cardiometabolic multimorbidity was defined as the presence of two or more CMDs. Data were analyzed using multi‐adjusted linear mixed‐effects models, Cox regression, and Laplace regression.
Results
CMD multimorbidity was associated with cognitive decline, CIND (hazard ratio [HR] 1.73; 95% confidence interval CI 1.23 to 2.44), and its progression to dementia (HR 1.86; 95% CI 1.17 to 2.97). CMD multimorbidity accelerated the onset of CIND by 2.3 years and dementia by 1.8 years.
Conclusions
CMD multimorbidity accelerates cognitive decline and increases the risk of both CIND and its conversion to dementia. Highlights We explored the combined impact of cardiometabolic diseases (CMDs) on cognition. An increasing number of CMDs dose‐dependently accelerated cognitive decline. CMD multimorbidity increased the risk of both cognitive impairment and dementia. Co‐morbid CMDs could be ideal targets for interventions to protect cognitive health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
- Department of Neurobiology, Care Sciences, and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
- Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Stockholm Gerontology Research Center, Stockholm, Sweden.
ORCID-Profile: Abigail Dove
Förderung
- the Swedish Ministry of Health and Social Affairs
- the Swedish Research Council
- the Swedish Council for Health Working Life and Welfare
- Lindhés Advokatbyrå AB
Zitieren
APA
Dove, A., Marseglia, A., Shang, Y., Grande, G., Vetrano, D. L., Laukka, E. J., Fratiglioni, L., & Xu, W. (2023). Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression. Alzheimer's & Dementia, 19(3), 821-830. https://doi.org/10.1002/alz.12708
Vancouver
Dove A, Marseglia A, Shang Y, Grande G, Vetrano DL, Laukka EJ, et al. Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression. Alzheimer's & Dementia. 2023;19(3):821-830. doi:10.1002/alz.12708
BibTeX
@article{Dove2023,
author = {Dove, Abigail and Marseglia, Anna and Shang, Ying and Grande, Giulia and Vetrano, Davide Liborio and Laukka, Erika J and Fratiglioni, Laura and Xu, Weili},
title = {Cardiometabolic multimorbidity accelerates cognitive decline and dementia progression},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {3},
pages = {821--830},
doi = {10.1002/alz.12708}
}
EUVIMED